News for PureTech Health plc (PRTC.L)

[url="]PureTech Health plc[/url] (Nasdaq: PRTC, LSE: PRTC) ("PureTech"), a clinical-stage biotherapeutics company, noted that its Founded Entity, [url="]Seapor

PureTech Health, identified by the ticker PRTC, has commenced the Phase 2b BUOY-1 clinical trial by dosing its first participant. This study is evaluating the e

PureTech Health plc (PRTC) announces the departure of CEO Bharatt Chowrira as Robert Lyne takes on the role of Interim CEO. Lyne assumes leadership with

PureTech Health (PRTC) has announced a significant leadership change with Bharatt Chowrira stepping down from his roles as CEO and board member. The company has

Summary: CEO transition at PureTech Health as Bharatt Chowrira steps down, with Robert Lyne stepping in as interim CEO. Analysts show a strong upside potenti

[url="]PureTech Health plc[/url] (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the li

Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.

PureTech Health plc (PRTC) successfully passed all resolutions at its Annual General Meeting on June 16, 2025. Resolutions 2 and 9 received less than 80

[url="]PureTech Health plc[/url] (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the li

[url="]PureTech Health plc[/url] (Nasdaq: PRTC, LSE: PRTC) (”œPureTech” or the ”œCompany”), a clinical-stage biotherapeutics company dedicated to changin

PureTech Health (PRTC) recently presented findings from their Phase 2b ELEVATE IPF trial at the 2025 American Thoracic Society conference in San Francisco. The

[url="]PureTech Health plc[/url] (Nasdaq: PRTC, LSE: PRTC) (”œPureTech” or the ”œCompany”), a clinical-stage biotherapeutics company dedicated to changin

PureTech Health (PRTC) has unveiled pivotal research featured in BMC Pulmonary Medicine, shedding light on the real-life challenges faced by individuals with id

New research published by PureTech Health (PRTC) reveals significant gaps in diagnosing and treating idiopathic pulmonary fibrosis (IPF). Findings empha

\nCash Position: $366.8 million at the PureTech level at the end of 2024, compared to $326 million at the end of 2023.Consolidated Cash Position: $367.3 million

The following slide deck was published by PureTech Health plc in conjunction with their 2024 Q4 earnings call.

PureTech Health plc (NASDAQ:PRTC) Q4 2024 Earnings Call April 30, 2025 9:00 AM ETCompany ParticipantsAllison Mead Talbot - Senior Vice President,...

Key Highlights: PureTech Health (PRTC) posts an impressive 45% growth in annual revenue. Analysts project a substantial price target upside, implying a p

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (”œPureTech” or the ”œCompany”) today announces its results for the year ended December 31, 2024, as well a